Upload
phungthien
View
216
Download
3
Embed Size (px)
Citation preview
1
2
BEST PRACTICES: APPLYING SCIENCE & LEVERAGING
EXPERIENCE FOR BETTER HEALTHKimberly Johnson, PhD
Director, Center for Substance Abuse TreatmentSubstance Abuse and Mental Health Services Administration
U.S. Department of Health & Human Services
24th Annual New England School of Best Practices in Addiction Treatment
Waterville Valley, NH August 29th, 2016
TODAY’S TOPICS
EPIDEMIOLOGY OF SUBSTANCE USE
EXPANDING ACCESS
IMPROVING QUALITY
EVIDENCE-BASED PRACTICE (EBP)
3
4
EPIDEMIOLOGY OF SUBSTANCE USE:SNAPSHOTS & TRENDS
+ Difference between this estimate and the 2014 estimate is statistically significant at the .05 level.
PAST MONTH ALCOHOL USE
5
People Aged 12 or Older by Age Group: 2002-2014
CURRENT, BINGE, AND HEAVY ALCOHOL USE
6
People Aged 12 or Older: 2014
+ Difference between this estimate and the 2014 estimate is statistically significant at the .05 level.
YOUTH: CURRENT, BINGE, AND HEAVY ALCOHOL USE
7
People Aged 12 to 20: 2002-2014
+ Difference between this estimate and the 2014 estimate is statistically significant at the .05 level.
PAST MONTH ILLICIT DRUG USE
8
People Aged 12 or Older by Age Group: 2002-2014
NUMBER OF PAST MONTH ILLICIT DRUG USERS
Note: Estimated numbers of people refer to people aged 12 or older in the civilian, noninstitutionalized population in the United States. The numbers do not sum to the total population of the United States because the population for NSDUH does not includepeople aged 11 years old or younger, people with no fixed household address (e.g., homeless or transient people not in shelters), active-duty military personnel, and residents of institutional group quarters, such as correctional facilities, nursing homes, mental institutions, and long-term hospitals.
Note: The estimated numbers of current users of different illicit drugs are not mutually exclusive because people could have used more than one type of illicit drug in the past month. Illicit Drugs include marijuana/hashish, cocaine (including crack), heroin, hallucinogens, inhalants, or prescription-type psychotherapeutics used nonmedically. 9
People Aged 12 or Older: 2014
NUMBER OF PEOPLE WITH A PAST YEAR SUD
SUD = substance use disorder. Note: SUD refers to dependence or abuse in the past year related to the use of alcohol or illicit drugs in that same period.
Estimated numbers of people having disorders for specific substances do not sum to the 21.5 million people with any SUD because people could have disorders associated with their use of more than one substance. 10
People Aged 12 or Older: 2014
+ Difference between this estimate and the 2014 estimate is statistically significant at the .05 level.
ALCOHOL USE DISORDER IN THE PAST YEAR
11
People Aged 12 or Older by Age Group: 2002-2014
+ Difference between this estimate and the 2014 estimate is statistically significant at the .05 level.
ILLICIT DRUG USE DISORDER IN THE PAST YEAR
12
People Aged 12 or Older by Age Group: 2002-2014
+ Difference between this estimate and the 2014 estimate is statistically significant at the .05 level.
MARIJUANA USE DISORDER IN THE PAST YEAR
13
People Aged 12 or Older by Age Group: 2002-2014
14
CPDs & HEROIN
Controlled prescription drugs (CPDs) and heroin are ranked as the most significant drug threats to the U.S.• Deaths attributable to CPDs
have outpaced those for cocaine and heroin combined.
• A subset of opioid CPD users are initiating heroin use.2015 NDTAS data sources include the DEA,
SAMHSA, CDC, NIDA, & other federal, state, and local data systems. http://www.dea.gov/docs/2015%20NDTA%20Report.pdf
15
OPIOID OVERDOSES ARE DRIVING INCREASE
https://www.cdc.gov/drugoverdose/data/statedeaths.html
+ Difference between this estimate and the 2014 estimate is statistically significant at the .05 level.
PAST MONTH NONMEDICAL USE OF PAIN RELIEVERS
16
People Aged 12 Or Older By Age Group: 2002-2014
+ Difference between this estimate and the 2014 estimate is statistically significant at the .05 level.
PAST YEAR PAIN RELIEVER INITIATES
17
People Aged 12 Or Older By Age Group: 2002-2014
+ Difference between this estimate and the 2014 estimate is statistically significant at the .05 level.
PAST YEAR PAIN RELIEVER USE DISORDER
18
People Aged 12 Or Older By Age Group: 2002-2014
32% of individuals with chronic pain (CP)estimated to have addictive disorders.
29-60% of people with opioid addictions report CP.
CP & addiction are dynamic conditions that can fluctuate in intensity over time.
Both require multimodal interventions; and treatment for one may impede or conflict with treatment for the other.
Both have serious consequences if left untreated.
CHRONIC PAIN AND SUDs
+ Difference between this estimate and the 2014 estimate is statistically significant at the .05 level.
PAST MONTH HEROIN USE
* Insufficient data available.
20
PEOPLE AGED 12 OR OLDER BY AGE GROUP: 2002-2014
+ Difference between this estimate and the 2014 estimate is statistically significant at the .05 level.
PAST YEAR HEROIN INITIATES
21
PEOPLE AGED 12 OR OLDER BY AGE GROUP: 2002-2014
+ Difference between this estimate and the 2014 estimate is statistically significant at the .05 level.
HEROIN USE DISORDER IN THE PAST YEAR
22
PEOPLE AGED 12 OR OLDER, BY AGE GROUP
Current data does not unequivocally support a causal link between policies implemented to reduce prescription drug misuse/abuse/diversion and an increase use of heroin.– In the majority of studies, the increase in the rates of
heroin use preceded changes in prescription-opioid policies, and there is no consistent evidence of an association between the implementation of policies related to prescription opioids and increases in the rates of heroin use or deaths, although the data are relatively sparse. Compton, WM et al, N Engl J Med 2016;374:154-63
HEROIN USE & NMU OF RX OPIOIDS (2)
ASSOCIATIONS BETWEEN POLYSUBSTANCE USE AND HEROIN USE
SAMHSA NSDUH Data 2011-2013, CDC Infographic
25
ASSOCIATION OF HEROIN ADDICTION RATES & OD DEATHS
26
DRUG POISONING MORTALITY BY U.S. COUNTY: 2004 & 2014
Since 2000, the rate of deaths from drug overdoses has increased 137%, including a 200% increase in the rate of overdose deaths involving opioids. -- CDC
27
AGE-ADJUSTED RATES OF DRUG OVERDOSE DEATHS BY STATE, 2014
https://www.cdc.gov/drugoverdose/data/statedeaths.html
28
DRUG OVERDOSE DEATH RATE INCREASE 2013 TO 2014
https://www.cdc.gov/drugoverdose/data/statedeaths.html
29
NATIONAL DISCONNECT: OUD TREATMENT & FOLLOW-UP SERVICES
http://www.samhsa.gov/data/sites/default/files/report_2117/ShortReport-2117.pdf
30
EXPANDING ACCESS
30
31
EXPANDING ACCESS REQUIRES COORDINATED ACTION ACROSS MULTIPLE SECTORS
32
HHS SECRETARY BURWELL’S OPIOID INITIATIVE
Medication-Assisted TreatmentTraining and Educational ResourcesNaloxone
33
BUPRENORPHINE FINAL RULE
https://www.federalregister.gov/articles/2016/07/08/2016-16120/medication-assisted-treatment-for-opioid-use-disorders
34
CARA 2016
https://www.congress.gov/bill/114th-congress/senate-bill/524/text?
35
SECTION 223 DEMONSTRATION PROJECT
http://www.samhsa.gov/section-223
36
“WE, AS CLINICIANS, ARE UNIQUELY POSITIONED TO TURN THE TIDE ON THE OPIOID EPIDEMIC.”
BE THE SOLUTION. JOIN THE MOVEMENT: http://turnthetiderx.org/
37
https://www.effectivehealthcare.ahrq.gov/ehc/products/636/2225/opioid-use-disorder-draft-report-160513.pdf
TREATMENT MODELS FOR OUD IN PRIMARY CARE SETTINGS
38
Using Data to Target Resources
IDENTIFYING HIGH RISK TARGET AREAS FOR OUD SERVICES
IMPROVING DATA: SPARS
SAMHSA’s Performance Accountability AndReporting System (SPARS):• Establish a common data & reporting system for
discretionary grants• Provide programmatic TA on data use for
grantees• Improve grant management; performance
monitoring; quality of services delivered; and health outcomes.
27
HSB Landing PageIZJTableau Reader- HSBo.shboard Si ' -Final for '
File Dashboard Window Help. -.. - - - -- - - -- - - - - - - -
. .1 . LSelecta Backgound MapHIV
Health Systems Branch Program Map Top 5 WellServed StatesNewYorlt
CalfforniaTexas
FloridaIllinois
42
29
14
11
11
Bottom 10Underserved StatesArkansas
Kentucky
Maryland
+
HIVCase rate In the 2014
D 0.0 - 7.3
7.3 - 14.6
14.6 - 22.0D•• 22.0 - 29.3
29.3 - 36.6
[Program• HIV• MAT-POOA
I• SBIRT
Missi11ippi
OklahomaWest Virginia
0
0
0
Gender1.41%
ClOpenStreetMap contooutors
.. I . Race..tA•l Q G
.0511
-•osu
u 0.77% 0.99%MPGU
.....I>OSU •osu I>OSU I>OSU I>OSU
Current29.83%
NotLatino
Latino
,. .EE Main Dash EE HNDash USAHN VIHN MPHN GUHN ASHN PRHN DCHN AKHN HIHN USADea AKDea H!Dea DCDea PRDea ASDea GUDea MPDea VIDea USANoP AKNoP
Program Program Discnption FundingAmount
Number of Pe
Grants
riodIntake
h
CurrentFollow Up#s
HIV Human lmmunodelicien<y VIUS 51 964,689 132 27.731 13,770MAT-POOA
Medicaboo-AsSISted Treatment Prescnpbon Drug andOpoood Addicbon
11
SBIRT Screenng Brief InterventiOn and Referral to Treatment 103
PROGRAM-LEVEL VIEW (TEAM HIV)
GRANTEE-LEVEL VIEW (mock data)
IMPROVING QUALITY
44
SAMHSA’S ALIGNMENT WITH 2015 IOM RECOMMENDATIONS
Report sponsors included SAMHSA, NIH, VA, APA, & NASW.
http://iom.nationalacademies.org/Reports/2015/Psychosocial-Interventions-Mental-Substance-Abuse-Disorders.aspx
24
IOM’s ITERATIVE FRAMEWORK FOR DEVELOPING STANDARDS
25http://iom.nationalacademies.org/Reports/2015/Psychosocial-Interventions-Mental-Substance-Abuse-Disorders.aspx
QUALITY MEASURES
http://www.samhsa.gov/data/national-behavioral-health-quality-framework#overview
http://www.qualityforum.org/Publications/2015/
QUALITY CONCERNS: SELECT EXAMPLES
48
Residential Rehab Sober Housing Peer support roles and reimbursement
EVIDENCE-BASED TREATMENT
http://www.samhsa.gov/find-help
50
EBP IS DATA DRIVEN, CONSTANTLY EVOLVING, AND NECESSARILY ADAPTIVE
http://www.samhsa.gov/ebp-web-guide/substance-abuse-treatment
51
EVIDENCE-BASED TREATMENTS:ONE SIZE DOES NOT FIT ALL
Just as individuals vary in their susceptibility tochronic diseases, individuals vary in their responseto treatments. •For some, behavioral & psychosocial
interventions may be effective & sufficient• For others, these interventions may need
to occur in conjunction with medication • Different medications may be more effective
& appropriate for different individuals
52
DETOXIFICATION IS NOT SUFFICIENT AS A STAND ALONE TREATMENT
Placebo Controlled Study of Maintenance vs. Detoxification with Buprenorphine
Kaplan-Meier curve of cumulative retention in treatment
Kakko J et al. Lancet.361(9358):662-8.2003.
53
MEDICATION ASSISTED TREATMENT
MAT, in principal, is widely used to treat a number of chronic diseases including heart disease and diabetes.• Medications are used where it is determined to
be medically necessary and appropriate.MAT is not a stand-alone treatment choice.
• It is part of an overall EB treatment program that can include behavioral, cognitive, & other interventions.
54
Provides effective, evidence-based medicines to treat opiate disorders to help stabilize the physiological & social effects of opiate addiction.• Improves individual – as well as public –
health & safety.• Facilitates recovery, thereby positively
influencing personal well-being and productivity as well as providing net economic benefits for society.
EVIDENCE-BASED OUD MAT
55
EBP: METHADONE IMPROVES OUTCOMES
56
78%
37%45%
0102030405060708090
100
Buprenorphine Referral Brief Intervention
% e
ngag
ed in
trea
tmen
t on
the
30th
day
afte
r ran
dom
izat
ion
5.4
2.3
Number of days of illicit opiate use per week
5.4
0.9
5.6
2.4
EBP: BUPRENORPHINE IN THE ED
Increased Engagement in Treatment & Reduced Illicit Opioid Use
Data: D’Onofrio, et al. JAMA. 2015.Slide adapted from Dr. W. Compton, 2016.
57Lee JD et al. N Engl J Med 2016;374:1232-1242. Slide adapted from Dr. W. Compton NIDA 2016.
RCT: N=308
EBP: NALTREXONE-XR
58
Heroin overdoses Buprenorphine treatmentMethadone treatment
EBP: MAT CAN DECREASE HEROIN OD DEATHS
Baltimore, Maryland, 1995-2009
Schwartz RP et al., Am J Public Health. 2013. Slide adapted from Dr. W. Compton NIDA 2016.
59
CSAT’s FY 2016 budget is approximately $2.2 billion.• $1.858 billion for the Substance Abuse
Prevention and Treatment Block Grant (SABG)
• $334 million for CSAT’s discretionary portfolio
SAMHSA CSAT FY16 OPERATING BUDGET
60
SELECT CSAT GRANT PROGRAMS
Substance Abuse Prevention and Treatment Block Grant (SABG)
Targeted Capacity Expansion (MAT PDOA; PTP; TAC)
Screening, Brief Intervention, and Referral to Treatment (SBIRT)
Opioid Treatment Programs & Regulatory Activities
Criminal Justice Minority AIDS Initiative (MAI)
Pregnant and Post Partum Women
Children and Families
Treatment Systems for Homeless
Recovery Community Services Program (RCSP)
61
TCE-MAT TCE-TACTCE-HIVTCE-PTP
TARGETED CAPACITY EXPANSION: FY2016 FOAs
62
TECHNOLOGY TRANSFER& WORKFORCE DEVELOPMENT
63
Focus on safe opioid prescribing
www.pcss-o.org
Focus on OUDtreatment
www.pcssmat.org
Focus on CME-accredited trainings on
safe use of opioids63
WORKFORCE TRAINING
64
WORKFORCE FY2016 FOAs
PCSS-MATMFP-ACSAMHSA-HRSA
http://www.samhsa.gov/grants/grant-announcements-2016
65
TELEHEALTH
http://www.asam.org/education/live-online-cme/fundamentals-of-addiction-medicine/recognition-program/teleecho-clinics
OTP SCPMobile AppsECHO
IMPROVING OUTCOMES THROUGH HIT
Content on this slide is for educational purposes only; there is no explicit nor implicit endorsement of services or products.
OTP SERVICE CONTINUITY PROJECT (SCP)
http://blog.samhsa.gov/2015/11/13/providing-otp-services-during-service-disruptions/#.Vw-eGs8XRPP
Use of a Health Information Exchange (HIE) to facilitate the exchange of dosing and associated demographic information between OTPs during a service interruption or a temporary client relocation, in accordance with client preferences.
All activities and systems are compliant with 42 CFR Part 2
MOBILE APPS
68
Content on this slide is for educational purposes only; there is no explicit nor implicit endorsement of services or products.
OPIOID RECOVERY APP CHALLENGE
http://samhsaopioidrecoveryapp.devpost.com/
Content on this slide is for educational purposes only; there is no explicit nor implicit endorsement of services or products.
70
LEARNING HEALTH CARE SYSTEMS INTEGRATE EBP + PBE
IOM (NAM): Science, informatics, incentives, and culture are aligned for continuous improvement and innovation, with best practices seamlessly embedded in the delivery process and new knowledge captured as an integral byproduct of the delivery experience.
Combines/integrates: Evidence-Based Practice (EBP) + Practice-Based Evidence (PBE)• Synergistic & dynamic evolution of knowledge,
best practices, and guidelines
71
THANK [email protected]
APPLYING SCIENCE & LEVERAGING EXPERIENCEFOR BETTER HEALTH
https://www.recoverymonth.gov/